S-Ruxolitinib

CAS No. 1160597-27-2

S-Ruxolitinib( —— )

Catalog No. M19421 CAS No. 1160597-27-2

Ruxolitinib (INCB018424) is the first potent selective JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    S-Ruxolitinib
  • Note
    Research use only, not for human use.
  • Brief Description
    Ruxolitinib (INCB018424) is the first potent selective JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays.
  • Description
    Ruxolitinib (INCB018424) is the first potent selective JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays >130-fold selectivity for JAK1/2 versus JAK3.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    JAK
  • Recptor
    JAK1| JAK2
  • Research Area
    Cardiovascular Disease
  • Indication
    Myelofibrosis; Polycythaemia Vera

Chemical Information

  • CAS Number
    1160597-27-2
  • Formula Weight
    306.37
  • Molecular Formula
    C17H18N6
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:61 mg/mL;Water:<1 mg/mL
  • SMILES
    N#CCC(C1CCCC1)n2cc(cn2)c4ncnc3nccc34
  • Chemical Name
    3-(4-(7H-Pyrrolo[23-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Quintas-Cardama A et al. Blood 2010 115(15) 3109-3117.
molnova catalog
related products
  • Fosifidancitinib

    Fosifidancitinib is a potent inhibitor of JAK 1 and JAK 3.

  • JAK1-IN-8

    JAK1-IN-8, a specific inhibitor of Janus kinase 1 (JAK1, IC50<500 nM).

  • AZ960

    A potent, selective JAK2 inhibitor with Ki of 0.45 nM, IC50 of <3 nM.